# Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

> **NCT03650894** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Providence Health & Services** · enrollment: 30 (actual)

## Conditions studied

- Breast Neoplasm Female
- Breast Cancer
- Breast Carcinoma
- Breast Tumor

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT03650894
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-03
- **Primary completion:** 2023-03-10
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03650894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03650894, "Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03650894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*